Replies to post #281095 on Amarin Corp Plc (AMRN)

[postes]

[north40000]

You are wrong on several fronts:

1) Apotex is a familiar generic name here in States

2) Your basic error is thinking that certain claims of 6 Amarin patents relating to the Marine indication being invalid somehow leaves Amarin in a hopeless situation

3) You are ignoring the 40-50 patents in the Orange Book that relate to the new Reduce-It indication. Amarin has a statutory exclusivity against the world that was granted by the FDA in December 2019 when the FDA approved the Amarin sNDA for the new Reduce-It indication. That statutory exclusivity expires in December 2022. That statutory exclusivity or monopoly is separate from any patent exclusivity....[more later, if necessary]